Sign In
Buy GLUE
$16.52
-6.16 (-27.16%)
At Close: Jul 31, 2026
Monte Rosa Therapeutics Announces Collaboration with Novartis for Degraders to Treat Immune-mediated Diseases
04:00am, Monday, 15'th Sep 2025
Novartis receives an exclusive license to an undisclosed discovery target Novartis also receives options to license two programs from Monte Rosa's growing preclinical immunology portfolio Monte Rosa
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
07:00am, Tuesday, 02'nd Sep 2025
BOSTON, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today an
Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Tops Revenue Estimates
09:26am, Thursday, 07'th Aug 2025
Monte Rosa Therapeutics (GLUE) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to a loss of $0.43 per share a year ago.
Monte Rosa Therapeutics Announces Second Quarter 2025 Financial Results and Business Updates
07:00am, Thursday, 07'th Aug 2025
Phase 1 study of NEK7-directed molecular glue degrader (MGD) MRT-8102 underway, to investigate a potential novel therapeutic approach for treating inflammatory diseases driven by the NLRP3 inflammasom
MRT-8102 Phase 1 study includes single and multiple ascending dose cohorts in healthy volunteers and is designed to evaluate safety, pharmacokinetics, NEK7 protein degradation, and other key downstrea
Monte Rosa Announces Publication in Science of Key Insights that Enable Next Generation Molecular Glue Degrader Medicines
02:15pm, Thursday, 03'rd Jul 2025
BOSTON, July 03, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today ann
Monte Rosa Therapeutics Announces FDA Clearance of IND Application for MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inf
Wall Street Analysts Think Monte Rosa Therapeutics (GLUE) Could Surge 222.16%: Read This Before Placing a Bet
11:01am, Monday, 09'th Jun 2025
The mean of analysts' price targets for Monte Rosa Therapeutics (GLUE) points to a 222.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreeme
Monte Rosa Therapeutics to Participate in the Jefferies Global Healthcare Conference
07:00am, Wednesday, 28'th May 2025
BOSTON, May 28, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today anno
Monte Rosa Therapeutics (GLUE) Tops Q1 Earnings and Revenue Estimates
09:25am, Thursday, 08'th May 2025
Monte Rosa Therapeutics (GLUE) came out with quarterly earnings of $0.57 per share, beating the Zacks Consensus Estimate of a loss of $0.24 per share. This compares to loss of $0.53 per share a year a
Monte Rosa Therapeutics Announces First Quarter 2025 Financial Results and Business Updates
07:00am, Thursday, 08'th May 2025
VAV1-directed MRT-6160 program advancing toward multiple Phase 2 studies, enabled by Phase 1 SAD/MAD study data supporting broad potential application in immune-mediated diseases MRT-2359 Phase 1/2 st
CDK2 molecular glue degrader (MGD) in combination with CDK4/6 inhibition and anti-estrogen therapy achieved superior tumor regression in vivo compared to standard of care CDK4/6 inhibition and anti-es
Monte Rosa Therapeutics, Inc. (GLUE) Q4 2024 Earnings Call Transcript
12:00pm, Thursday, 20'th Mar 2025
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE ) Q4 2024 Results Conference Call March 20, 2025 8:00 AM ET Company Participants Andrew Funderburk - Senior Vice President, Investor Relations and Strategic
Monte Rosa Therapeutics (GLUE) Q4 Earnings and Revenues Top Estimates
11:35am, Thursday, 20'th Mar 2025
Monte Rosa Therapeutics (GLUE) came out with quarterly earnings of $0.23 per share, beating the Zacks Consensus Estimate of a loss of $0.37 per share. This compares to loss of $0.58 per share a year a
Results of the MRT-6160 Phase 1 SAD/MAD study demonstrate deep VAV1 degradation of greater than 90%, significant T and B cell functional inhibition as well as significant inhibition of cytokine releas
